Evidence map›Paper›PMID 42334742›Full record

ArticleMolecular biology reports2026

Interplay between CDH1 polymorphisms, haplotypes, and genomic repetitive elements in urothelial bladder cancer prognosis.

Laís Capelasso Lucas Pinheiro, Maria Alice Feitosa de Souza Martins, Maria Fernanda Vicente Turim, Isabely Mayara da Silva, Janaina Nicolau de Oliveira, Fernando Terziotti, Juliana Mara Serpeloni, Karen Brajão de Oliveira, André Luís Laforga Vanzela, Roberta Losi Guembarovski

Abstract read
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Laís Capelasso Lucas PinheiroLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil.ORCID http://orcid.org/0000-0003-3444-1210
Maria Alice Feitosa de Souza MartinsLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil.ORCID http://orcid.org/0009-0005-4562-1753
Maria Fernanda Vicente TurimLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil.ORCID http://orcid.org/0009-0009-2005-1781
Isabely Mayara da SilvaLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil.ORCID http://orcid.org/0009-0007-7488-5760
Janaina Nicolau de OliveiraLaboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Londrina State University, Londrina, PR, Brazil.ORCID http://orcid.org/0000-0002-0303-0382
Fernando TerziottiCancer Hospital of Londrina - HCL, Londrina, PR, Brazil.ORCID http://orcid.org/0000-0002-5086-1621
Juliana Mara SerpeloniLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil.ORCID http://orcid.org/0000-0001-9846-5807
Karen Brajão de OliveiraLaboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Londrina State University, Londrina, PR, Brazil.ORCID http://orcid.org/0000-0001-9666-6963
André Luís Laforga VanzelaLaboratory of Cytogenetics and Plant Diversity, Department of General Biology, Londrina State University, Londrina, PR, Brazil.ORCID http://orcid.org/0000-0002-2442-2211
Roberta Losi GuembarovskiLaboratory of Mutagenesis and Oncogenetics, Department of General Biology, Londrina State University, Londrina, PR, Brazil. robertalosi@uel.br.ORCID http://orcid.org/0000-0002-6291-8621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrothelial Bladder Cancer (UBC) remains a significant clinical challenge due to its high morbidity, substantial economic burden, and high recurrence rates. E-cadherin, an important regulator of cell-cell adhesion encoded by the CDH1 gene, is frequently downregulated during malignant progression, serving as a hallmark of invasiveness. This study explored the prognostic significance of CDH1 genetic variants (rs16260 C > A and rs7186053 A > G) and haplotypes, while integrating bioinformatic profiling of repetitive elements. METHODS AND

resultsA cohort of 334 UBC patients was genotyped via qPCR, followed by haplotype reconstruction and association with clinical outcomes. This analysis was complemented by immunofluorescence to illustrate the interplay between tissue invasion levels and CDH1 genetic backgrounds in selected samples. Bioinformatic tools characterized the CDH1 genomic repeat elements landscape. The rs16260 heterozygous genotype was significantly associated with a reduced risk of 1-year recurrence (p < 0.05). Moreover, the CG haplotype emerged as a protective factor against recurrence within two years. Illustrative immunofluorescence analysis confirmed the loss of E-cadherin and epithelial disorganization in muscle-invasive samples compared to non-invasive tumors. Notably, bioinformatic screening revealed a complex architecture of repetitive elements, including novel Alu insertions within Exon 16, indicating potential regulatory hubs.

conclusionOur findings demonstrate that CDH1 polymorphisms and haplotype structures are potential modulators of UBC recurrence. Furthermore, the identification of repetitive elements in crucial genomic segments highlights a new layer of transcriptional regulation, offering promising approaches for the prognostic stratification and molecular targeting of bladder cancer.

Indexed as

Antigens, CDCadherinsUrinary Bladder NeoplasmsAgedFemaleGenetic Predisposition to DiseaseGenotypeHaplotypesHumansMaleMiddle AgedNeoplasm Recurrence, LocalPolymorphism, Single NucleotidePrognosisRepetitive Sequences, Nucleic AcidAntigens, CDCadherinsCDH1 protein, humanE-cadherinrs16260rs7186053SINEsTumoral recurrence

Identifiers

PMID42334742
PMCPMC13290822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.